# Fei Tian

> Fei Tian is a Series A investor at Vesalius Biocapital Partners backing Health Care. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Vesalius Biocapital Partners](https://shizune.co/investors/profile/vesalius-biocapital-partners)
- Total investments: 1
- Last investment: Jul 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/dr-fei-tian-0a543233

Fei Tian is a Series A investor at Vesalius Biocapital Partners focused on Health Care and Biotechnology. Fei Tian holds a MD (Medical Doctor) degree (2008) from Shanghai Tongji University, People’s Republic of China. She began her career as a physician in emergency medicine. During her work as a physician, she also performed research in atherosclerosis and immunology. She pursued her interest in pulmonary oncology research for her scientificific doctoral degree for a PhD at the Ludwig-Maximilian University and Thoracic Oncology Center, Munich, Germany. She has several publications as author and co-author in international peer-reviewed journals.In addition to her medical and scientific research background, she gained substantial experience of medical communication and life science consulting, including in-licensing of biological products, international market research and communication, and development of business strategies for global medtech companies and pharmaceutical companies.Fei Tian joined Vesalius Biocapital as an analyst in 2012.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SciRhom | SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development. | $68.1M | Series A | Jul 09, 2024 |  |

1 of 1 investments shown.

## Co-investors
- [Bayern Kapital](https://shizune.co/investors/profile/bayern-kapital) — VC Fund, 1 deal together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 1 deal together
- [Hadean Ventures](https://shizune.co/investors/profile/hadean-ventures) — VC Fund, 1 deal together
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund, 1 deal together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 1 deal together
- [PhiFund Ventures](https://shizune.co/investors/profile/phifund-ventures) — VC Fund, 1 deal together

## About Vesalius Biocapital Partners

VC Fund · Strassen, Luxembourg

Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.

5 contacts available at Vesalius Biocapital Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Fei Tian | Analyst | https://shizune.co/investors/profile/fei-tian |
| Guy Geldhof | Partner | https://shizune.co/investors/profile/guy-geldhof |
| Stephane Verdood | Managing Partner | https://shizune.co/investors/profile/stephane-verdood |
| Alain Parthoens | Managing Partner | https://shizune.co/investors/profile/alain-parthoens |
| Christian Schneider | Managing Partner | https://shizune.co/investors/profile/christian-schneider |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Fei Tian invest in?

Fei Tian invests primarily in Health Care and Biotechnology startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Fei Tian last invest?

The most recent investment recorded for Fei Tian closed in Jul 2024. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co